{
  "question_stem": {
    "en": "Healthy adult volunteers are enrolled in a phase I clinical trial investigating the properties of a newly developed oral antimicrobial agent. The drug is administered in different amounts to the volunteers over the course of several weeks to determine the best dosage that minimizes toxicity while maintaining trough levels above the minimum inhibitory concentration. While reviewing the data, the researchers note that the drug's half-life seems to vary amongst the study participants. An increase in which of the following pharmacologic parameters is most likely responsible for the longer half-life seen in certain individuals?",
    "zh": "健康成年志愿者参与一项 I 期临床试验，研究一种新开发的口服抗菌药物的特性。在几周的时间里，志愿者接受不同剂量的药物，以确定在最大限度地减少毒性的同时，维持谷浓度高于最低抑菌浓度的最佳剂量。在审查数据时，研究人员注意到该药物的半衰期在研究参与者之间似乎有所不同。以下哪种药理学参数的增加最有可能导致某些个体出现较长的半衰期？"
  },
  "question": {
    "en": "An increase in which of the following pharmacologic parameters is most likely responsible for the longer half-life seen in certain individuals?",
    "zh": "以下哪种药理学参数的增加最有可能导致某些个体出现较长的半衰期？"
  },
  "options": {
    "A": {
      "en": "Drug glucuronidation",
      "zh": "药物葡萄糖醛酸化"
    },
    "B": {
      "en": "Glomerular filtration rate",
      "zh": "肾小球滤过率"
    },
    "C": {
      "en": "Oral bioavailability",
      "zh": "口服生物利用度"
    },
    "D": {
      "en": "Peak serum drug levels",
      "zh": "峰值血清药物浓度"
    },
    "E": {
      "en": "Volume of distribution",
      "zh": "分布容积"
    }
  },
  "correct_answer": "E",
  "explanation": {
    "en": "The half-life (t½) is the time required for the plasma concentration of a drug with first-order elimination kinetics to decrease by 50%. At time zero, 100% of the drug is present, and with the passage of each subsequent half-life, half of the remaining drug is eliminated. After 5 half-life intervals, a drug is almost completely eliminated from the body. A drug's half-life depends on 2 pharmacokinetic properties: Clearance (CL) and Volume of distribution (Vd).\n\nClearance (CL) represents the volume of plasma completely cleared of a substance per unit time (eg, mL/min). The CL rate is constant for most drugs and depends on the particular metabolic conversion (eg, glucuronidation to inactive form) and/or elimination pathways (eg, biliary or urinary excretion) used to remove the drug from the body. Increased glucuronidation or glomerular filtration would increase plasma CL of the drug, leading to decreased drug half-life (Choices A and B).\n\nVolume of distribution (Vd) refers to the extent to which a drug distributes in body tissue compared to its plasma concentration. A drug's Vd is determined by its intrinsic properties (eg, lipid solubility, protein binding), as well as patient factors such as body weight and composition (eg, increased fat vs lean mass). In general, a higher Vd means that the drug is increasingly bound to body tissues with a smaller proportion found in the plasma. Because plasma concentrations are lower for any given dose, drugs with higher Vd take longer to eliminate from the body and therefore have a longer half-life.\n\nThe half-life of a drug can be calculated using these parameters, as follows:\nt½ = (0.7 × Vd) / CL\n\nIn this case, the increased drug half-life seen in certain patients is likely due to increased total body weight, resulting in a higher volume of distribution.\n\n(Choices C and D) Oral bioavailability can vary between individuals due to intrinsic differences (eg, age, sex, disease), diet, and medications (eg, proton pump inhibitors). Although increased oral bioavailability can raise peak serum drug levels, drug half-life would not be affected because the amount of drug eliminated per unit time increases as the drug's plasma concentration increases (true of drugs exhibiting first-order kinetics, which account for the vast majority of clinically used drugs).\n\nEducational objective:\nHalf-life (t½) is a measure of how quickly a drug with first-order kinetics is eliminated from the body. A drug is almost completely eliminated after 5 half-life intervals. The half-life can be calculated from the drug's volume of distribution (Vd) and clearance rate (CL) using the following equation:\nt½ = (0.7 × Vd) / CL",
    "zh": "半衰期（t½）是指具有一级消除动力学的药物的血浆浓度降低 50% 所需的时间。在时间零点，药物的浓度为 100%，每经过一个半衰期，剩余药物的一半会被消除。经过 5 个半衰期后，药物几乎完全从体内清除。药物的半衰期取决于 2 个药代动力学特性：清除率 (CL) 和分布容积 (Vd)。\n\n清除率 (CL) 代表单位时间内完全清除某种物质的血浆体积（例如，mL/min）。对于大多数药物，CL 率是恒定的，它取决于用于从体内清除药物的特定代谢转化（例如，葡萄糖醛酸化为无活性形式）和/或消除途径（例如，胆汁或尿液排泄）。增加葡萄糖醛酸化或肾小球滤过会增加药物的血浆 CL，从而导致药物半衰期缩短（选项 A 和 B）。\n\n分布容积 (Vd) 是指药物在身体组织中分布的程度与血浆浓度相比。药物的 Vd 由其内在特性（例如，脂溶性、蛋白质结合）以及患者因素（如体重和组成，例如，脂肪增加与瘦体重）决定。一般来说，较高的 Vd 意味着药物越来越多地与身体组织结合，而血浆中的比例较小。由于任何给定剂量的血浆浓度较低，因此 Vd 较高的药物需要更长的时间才能从体内清除，因此具有更长的半衰期。\n\n可以使用以下参数计算药物的半衰期：\nt½ = (0.7 × Vd) / CL\n\n在这种情况下，某些患者中观察到的药物半衰期增加很可能是由于总体重增加，导致分布容积增加。\n\n（选项 C 和 D）口服生物利用度可能因个体差异（例如，年龄、性别、疾病）、饮食和药物（例如，质子泵抑制剂）而异。虽然口服生物利用度增加可以提高峰值血清药物浓度，但药物半衰期不会受到影响，因为单位时间内消除的药物量会随着药物血浆浓度的增加而增加（对于表现出一级动力学的药物，这是正确的，这些药物占临床使用药物的绝大多数）。\n\n教育目标：\n半衰期 (t½) 是衡量具有一级动力学的药物从体内消除速度的指标。经过 5 个半衰期后，药物几乎完全被消除。可以使用以下公式根据药物的分布容积 (Vd) 和清除率 (CL) 计算半衰期：\nt½ = (0.7 × Vd) / CL"
  },
  "summary": {
    "en": "This question tests the understanding of pharmacokinetic principles, specifically the factors that influence a drug's half-life. It requires the ability to relate changes in drug half-life to alterations in clearance and volume of distribution.\n\nTo solve this question, one must recall the formula for drug half-life and understand how clearance and volume of distribution affect it. By analyzing the relationship between these parameters, the most likely cause for an increased half-life can be identified.",
    "zh": "这个问题考察对药代动力学原理的理解，特别是影响药物半衰期的因素。它要求能够将药物半衰期的变化与清除率和分布容积的变化联系起来。\n\n要解决这个问题，必须回忆药物半衰期的公式，并理解清除率和分布容积如何影响它。通过分析这些参数之间的关系，可以确定半衰期增加的最可能原因。"
  },
  "tags": "Pharmacokinetics; Drug half-life; Clearance; Volume of distribution; First-order kinetics; Drug metabolism; Drug excretion",
  "category": "Pharma",
  "question_id": "1714",
  "has_exhibits": true,
  "exhibit_count": 4,
  "exhibit_files": [
    "image1.jpg",
    "image2.jpg",
    "image3.jpg",
    "image4.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Pharma 23\\1714",
  "extracted_at": "2025-11-05T19:45:05.114456",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 2,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T18:47:06.066927",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}